A Survey of Patient Experience in CML: American and Canadian Perspectives.

With treatment, chronic myeloid leukemia (CML) has a favorable prognosis, however, individuals with CML experience impairment to their quality of life (QoL). The aim of this study was to examine the perspectives and experiences of individuals with CML and to understand their challenges communicating with their CML physician. An online survey in adults with CML (n=100) in the US and Canada assessed QoL, patient-provider relationships, treatment satisfaction, and understanding of CML and treatment goals via the MD Anderson Symptom Inventory, the Cancer Therapy Satisfaction Questionnaire and de novo survey questions. Participants were recruited via an external patient recruiter and CML Patient Groups. Many participants reported hardships due to CML and its treatment. The main impacts were on the ability to work (21%), engage in personal activities (e.g., hobbies, 28%), and to enjoy sexual relations (median=2.00, IQR=8.50). A substantial proportion (21-39%) wished to discuss additional topics with their providers (e.g., management of CML and/or its impacts). While participants reported satisfaction with therapy overall (median=85.71, IQR=17.86), they indicated low to moderate treatment satisfaction with specific components, including concerns regarding side effects (median=43.75, IQR=43.75). Participants generally had a good understanding of CML (97%) and its treatment goals (92%). These findings advance our understanding of issues that need improvement to support QoL for individuals living with CML. Future work is needed to improve patient-provider relationships, address treatment-related side effects, and provide clinical information that is easier for patients to understand.

Informations de copyright

© 2023 Hillis et al.

Déclaration de conflit d'intérêts

EHG, TSML, JV, and SD are employees of Pfizer Inc. RB, HFB, ADP, and VB, employees of ICON, received consultancy fees from Pfizer. KEF and CH received consultancy fees from Pfizer. CH also reports grants from Novartis, outside the submitted work. KEF also reports consultancy fees from Inhibikase and grant to her institution from Novartis, outside the submitted work. EA receives research support and consultancy fees from Novartis and Takeda, and consultancy fees from BMS, Abbvie and Pfizer. The remaining authors report no conflicts of interest in this work.